Ciduvectamig Biosimilar – Anti-TMEFF2, CD3E mAb – Research Grade from ProteoGenix; catalogue PX-TA2055; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ciduvectamig Biosimilar: A Powerful Antibody Targeting TMEFF2 and CD3E for Therapeutic Use
Ciduvectamig Biosimilar is a novel antibody that has been developed as a biosimilar version of the existing anti-TMEFF2 and CD3E monoclonal antibodies. This biosimilar is designed to target and bind to both TMEFF2 and CD3E, making it a powerful therapeutic tool for various diseases. In this article, we will discuss the structure, activity, and potential applications of Ciduvectamig Biosimilar in more detail.
Ciduvectamig Biosimilar is a recombinant humanized monoclonal antibody that is produced using advanced biotechnology techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to the target molecules, TMEFF2 and CD3E.
Ciduvectamig Biosimilar has a dual mechanism of action, targeting both TMEFF2 and CD3E. TMEFF2 is a transmembrane protein that is overexpressed in many types of cancer, including breast, lung, and prostate cancer. By binding to TMEFF2, Ciduvectamig Biosimilar inhibits its activity and prevents the growth and spread of cancer cells.
CD3E, on the other hand, is a protein found on the surface of T cells. It plays a crucial role in the activation and proliferation of T cells, which are important for the immune response against infections and cancer. Ciduvectamig Biosimilar binds to CD3E and modulates its activity, leading to the activation of T cells and enhancing the immune response.
Ciduvectamig Biosimilar has shown great potential in the treatment of various diseases, particularly cancer. Its ability to target both TMEFF2 and CD3E makes it a promising therapeutic option for different types of cancer. It can be used as a monotherapy or in combination with other cancer treatments, such as chemotherapy and radiation therapy.
Moreover, Ciduvectamig Biosimilar has also shown promise in the treatment of autoimmune diseases. By modulating the activity of CD3E and activating T cells, it can help regulate the immune response and reduce inflammation in diseases such as rheumatoid arthritis and multiple sclerosis.
Additionally, Ciduvectamig Biosimilar can also be used in research settings as a research-grade antibody. Its high specificity and potency make it a valuable tool for studying the role of TMEFF2 and CD3E in various diseases and for developing new treatments.
In conclusion, Ciduvectamig Biosimilar is a powerful antibody that targets both TMEFF2 and CD3E. Its unique structure and dual mechanism of action make it a promising therapeutic option for various diseases, particularly cancer and autoimmune diseases. Its potential applications in both clinical and research settings make it a valuable addition to the field of biotechnology and medicine.
ProteoGenix catalogue number PX-TA2055. For research use only.
Target: Ciduvectamig Biosimilar – Anti-TMEFF2, CD3E mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Ciduvectamig Biosimilar – Anti-TMEFF2, CD3E mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
